G01N 2400/40
Glycosaminoglycans, i.e. gag or mucopolysaccharides
Official title: Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
G01N2400/40 (Glycosaminoglycans, i.e. gag or mucopolysaccharides) appears on 297 US grants and 324 published applications in this corpus.
Search patents in G01N- Granted patents
- 297
- Published applications
- 324
- Assignees
- 243
- Inventors
- 732
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 2 | 0 |
| 1979 | 1 | 0 |
| 1980 | 6 | 0 |
| 1981 | 2 | 0 |
| 1982 | 2 | 0 |
| 1983 | 4 | 0 |
| 1984 | 2 | 0 |
| 1985 | 3 | 0 |
| 1986 | 1 | 0 |
| 1987 | 3 | 0 |
| 1988 | 0 | 0 |
| 1989 | 8 | 0 |
| 1990 | 3 | 0 |
| 1991 | 1 | 0 |
| 1992 | 3 | 0 |
| 1993 | 3 | 0 |
| 1994 | 6 | 0 |
| 1995 | 5 | 0 |
| 1996 | 4 | 0 |
| 1997 | 8 | 0 |
| 1998 | 12 | 0 |
| 1999 | 15 | 0 |
| 2000 | 7 | 0 |
| 2001 | 7 | 5 |
| 2002 | 6 | 11 |
| 2003 | 8 | 6 |
| 2004 | 4 | 9 |
| 2005 | 4 | 6 |
| 2006 | 6 | 10 |
| 2007 | 3 | 13 |
| 2008 | 5 | 5 |
| 2009 | 4 | 12 |
| 2010 | 9 | 14 |
| 2011 | 9 | 15 |
| 2012 | 7 | 16 |
| 2013 | 11 | 15 |
| 2014 | 10 | 17 |
| 2015 | 14 | 23 |
| 2016 | 7 | 19 |
| 2017 | 7 | 15 |
| 2018 | 17 | 19 |
| 2019 | 10 | 14 |
| 2020 | 13 | 11 |
| 2021 | 7 | 13 |
| 2022 | 5 | 12 |
| 2023 | 6 | 11 |
| 2024 | 5 | 16 |
| 2025 | 7 | 10 |
| 2026 | 4 | 7 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Heparin-insensitive assay for factor XIa25 Aug 2026US 12,716,084 B2Takeda Pharmaceutical Company Limited
- Antibody-based method to identify, purify, and manipulate cell types and processes30 Jun 2026US 12,668,644 B2Albert Einstein College of Medicine
- Biomarkers of renal injury14 Apr 2026US 12,601,746 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Biomarker combinations to simultaneously evaluate non-alcoholic steatohepatitis and hepatic fibrosis status14 Apr 2026US 12,601,747 B2Bio-Rad Laboratories, Inc.
- Biomarkers for multiple sclerosis4 Nov 2025US 12,461,098 B2GLX Analytix ApS
- Improved blood diagnostic24 Sep 2026US 2026/0287598 A1Fujirebio Europe N.V.
- Recombinant var2csa protein, and preparation method and use thereof16 Jul 2026US 2026/0200996 A1Sun Yat-sen University Cancer Center (The Affiliated Cancer Hospital of Sun Yat-sen University, The
- Methods and Devices for Detecting Mechanical Forces Using Cas Nuclease and Guide RNA Complexes18 Jun 2026US 2026/0168007 A1Emory University
- Chondroitin Sulfate and Heparan Sulfate as Biomarkers for Discriminating Osteoarthritis and Rheumatoid Arthritis11 Jun 2026US 2026/0160757 A1Elypta AB
- Biomarkers for multiple sclerosis4 Jun 2026US 2026/0153508 A1GLX Analytix ApS
Most cited
By later US patents
- Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)104US 4,603,106 AThe Rockefeller University · 1986
- Nanocrystalline magnetic iron oxide particles-method for preparation and use in medical diagnostics and therapy101US 5,427,767 AInstitut fur Diagnostikforschung GmbH an der Freien Universitat Berlin · 1995
- Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)72US 4,822,776 AThe Rockefeller University · 1989
- Analysis of sulfated polysaccharides68US 7,575,886 B2Momenta Pharmaceuticals, Inc. · 2009
- Heparanase derived from human Sk-Hep-1 cell line55US 5,362,641 AHadassah Medical Organization Kiryat Hadassah · 1994